Clinical Trial Detail

NCT ID NCT01875666
Title Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Lapatinib + Trastuzumab

Trastuzumab

Pertuzumab

Pertuzumab + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST